Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 02:21PM ET
1.04
Dollar change
+0.01
Percentage change
0.97
%
Index- P/E- EPS (ttm)-2.35 Insider Own- Shs Outstand8.16M Perf Week4.00%
Market Cap11.12M Forward P/E- EPS next Y-3.45 Insider Trans- Shs Float8.15M Perf Month-16.47%
Income-20.59M PEG- EPS next Q- Inst Own12.12% Short Float0.71% Perf Quarter-26.76%
Sales0.01M P/S1111.76 EPS this Y-9.79% Inst Trans- Short Ratio0.23 Perf Half Y5.58%
Book/sh1.85 P/B0.56 EPS next Y-27.10% ROA-63.66% Short Interest0.06M Perf Year-53.57%
Cash/sh0.95 P/C1.10 EPS next 5Y- ROE-78.94% 52W Range0.87 - 6.41 Perf YTD-29.73%
Dividend Est.- P/FCF- EPS past 5Y15.44% ROI-102.98% 52W High-83.78% Beta-0.09
Dividend TTM- Quick Ratio4.87 Sales past 5Y-73.75% Gross Margin- 52W Low19.54% ATR (14)0.10
Dividend Ex-Date- Current Ratio3.81 EPS Y/Y TTM-8.74% Oper. Margin-137808.26% RSI (14)46.56 Volatility11.60% 9.01%
Employees- Debt/Eq0.05 Sales Y/Y TTM-92.14% Profit Margin-138260.67% Recom1.00 Target Price6.00
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q20.59% Payout- Rel Volume0.16 Prev Close1.03
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume251.77K Price1.04
SMA20-4.57% SMA50-2.94% SMA200-42.48% Trades Volume30,312 Change0.97%
Date Action Analyst Rating Change Price Target Change
Sep-28-23Upgrade H.C. Wainwright Neutral → Buy $8
Sep-28-23Reiterated Maxim Group Buy $7 → $10
Jan-10-22Initiated H.C. Wainwright Buy $54
Jan-10-22Initiated Evercore ISI Outperform $17
Jan-10-22Initiated Cantor Fitzgerald Overweight $52
Jan-10-22Initiated Berenberg Buy $21
Mar-21-24 06:00AM
Feb-22-24 04:30PM
Feb-05-24 03:11AM
Feb-04-24 11:01AM
Jan-22-24 06:00AM
06:00AM Loading…
Jan-05-24 06:00AM
Dec-06-23 08:00AM
Oct-30-23 02:02PM
Oct-16-23 08:00AM
Sep-29-23 08:51AM
12:13AM
Sep-28-23 08:03AM
07:09AM
06:00AM
Sep-14-23 06:00AM
11:50AM Loading…
Aug-24-23 11:50AM
Aug-23-23 06:00AM
Jul-31-23 06:00AM
Jul-25-23 06:00AM
Jul-15-23 08:27PM
Jul-03-23 06:00AM
Jun-15-23 08:00AM
May-30-23 06:00AM
Apr-28-23 06:00AM
Apr-27-23 06:00AM
Mar-09-23 10:54AM
Mar-08-23 07:00PM
Mar-03-23 09:55AM
Feb-24-23 03:05PM
Feb-23-23 06:00AM
07:02PM Loading…
Feb-05-23 07:02PM
Jan-30-23 06:23PM
Dec-19-22 03:29PM
09:30AM
Dec-18-22 07:34PM
Dec-15-22 06:35PM
Dec-02-22 06:00AM
Nov-21-22 06:13PM
Nov-16-22 06:36PM
Nov-02-22 06:00AM
Oct-25-22 06:00AM
Oct-18-22 06:00AM
Oct-07-22 04:39PM
Oct-04-22 06:00AM
Sep-21-22 06:00AM
Sep-15-22 09:55AM
Aug-31-22 06:00AM
Aug-30-22 09:55AM
Aug-27-22 06:26PM
Aug-25-22 06:00AM
Aug-08-22 06:00AM
Jul-29-22 06:00AM
Jul-08-22 06:00AM
Jun-27-22 06:00AM
Jun-24-22 07:44AM
Jun-13-22 04:30PM
May-16-22 06:00AM
May-10-22 08:00AM
Feb-23-22 09:00PM
Jan-14-22 07:06AM
Jan-12-22 06:00AM
Jan-05-22 05:58PM
Jan-03-22 06:00AM
Dec-16-21 06:00AM
Bionomics Ltd. is a clinical stage biopharmaceutical company. It engages in the development of novel drug candidates focused on the treatment of serious central nervous system disorders. Its lead product candidate is BNC210. The company was founded in 1996 and is headquartered in Eastwood, Australia.